Revenio Group Corporation (REG1V)

Currency in EUR
9.42
+0.15(+1.62%)
Real-time Data·
REG1V is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.209.49
52 wk Range
8.7423.40
Key Statistics
Prev. Close
9.27
Open
9.27
Day's Range
9.2-9.49
52 wk Range
8.74-23.4
Volume
49.86K
Average Volume (3m)
123.6K
1-Year Change
-59.0435%
Book Value / Share
5.33
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
REG1V Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.68
Upside
+23.94%
Members' Sentiments
Bearish
Bullish
ProTips
Short term obligations exceed liquid assets

Revenio Group Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Buy
Moving Averages
Strong Sell

Analyst Ratings

3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 11.68
(+23.94% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
RBC Capital
Buy23.50+150.80%26.00MaintainFeb 19, 2026
RBC Capital
Buy26.00+177.48%28.00MaintainDec 24, 2025

Revenio Group Corporation Earnings Call Summary for Q3/2026

  • Q3 net sales surged 130% to EUR 58.8M on Visionix acquisition, but adjusted EBITDA margin fell to 14.7% from 25.7% due to lower-margin profile.
  • Organic growth flat on pro forma basis; stock dropped 10.12% to $9.06 as investors focused on margin pressure over headline revenue gains.
  • Full-year 2026 revenue guidance narrowed to EUR 190-200M from EUR 190-205M; adjusted EBITDA outlook unchanged with EUR 5M of EUR 20M synergies secured.
  • U.S. sales reorganization completed August, weighing on Q3 North America sales; management expects improved cross-selling and commercial synergies in 2027.
  • ILLUME software FDA approval delayed to Q3-Q4 2027; NHS orders anticipated early 2027; net debt-to-EBITDA improved to 5.1x from 5.3x in Q2.
Last Updated: 12/11/2026, 14:56
Read Full Transcript

Earnings

Latest Release
Nov 12, 2026
EPS / Forecast
0.15 / 0.08
Revenue / Forecast
58.8M / 60.62M
EPS Revisions
Last 90 days

REG1V Income Statement

Compare REG1V to Peers and Sector

Metrics to compare
REG1V
Peers
Sector
Relationship
P/E Ratio
32.7x16.2x−0.2x
PEG Ratio
−0.880.510.00
Price/Book
2.5x1.5x2.6x
Price / LTM Sales
2.5x2.7x2.8x
Upside (Analyst Target)
24.1%16.2%65.0%
Fair Value Upside
Unlock12.8%9.5%Unlock

Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by veterinarians, ophthalmologists and other personnel to measure intraocular pressure in animal patients. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers iCare ILLUME, a screening software that helps to detect the early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma using artificial intelligence; iCare CLINIC cloud software to store long-term IOP data; and Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.

Employees
765
Market
Finland

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.04M4.86%18.92M
Other Institutional Investors
15.14M36.03%140.36M
Public Companies & Retail Investors
24.84M59.11%230.25M
Total
42.02M100.00%389.53M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
William Demant Invest A/S25.55%10,737,25299,534
SEB Funds AB2.91%1,220,69511,316

People Also Watch

10.15
SAMPO
-0.15%
125.70
CAPP
-1.33%
286.0
NOVOb
+2.69%
58.28
KNEBV
+0.14%
23.57
FORTUM
-0.80%

FAQ

What Is the Revenio Group (REG1V) Stock Price Today?

The Revenio Group stock price today is 9.42 EUR.

What Stock Exchange Does Revenio Group Trade On?

Revenio Group is listed and trades on the Helsinki Stock Exchange.

What Is the Stock Symbol for Revenio Group?

The stock symbol for Revenio Group is "REG1V."

What Is the Revenio Group Market Cap?

As of today, Revenio Group market cap is 394.15M EUR.

What Is Revenio Group's Earnings Per Share (TTM)?

The Revenio Group EPS (TTM) is 0.44.

When Is the Next Revenio Group Earnings Date?

Revenio Group will release its next earnings report on Feb 11, 2027.

From a Technical Analysis Perspective, Is REG1V a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Revenio Group Stock Split?

Revenio Group has split 4 times.

How Many Employees Does Revenio Group Have?

Revenio Group has 765 employees.

What is the current trading status of Revenio Group (REG1V)?

As of Nov 16, 2026, Revenio Group (REG1V) is trading at a price of 9.42 EUR, with a previous close of 9.27 EUR. The stock has fluctuated within a day range of 9.20 EUR to 9.49 EUR, while its 52-week range spans from 8.74 EUR to 23.40 EUR.

What Is Revenio Group (REG1V) Price Target According to Analysts?

The average 12-month price target for Revenio Group is 11.68 EUR, with a high estimate of 13 EUR and a low estimate of 9.9 EUR. 3 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +23.94% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.